You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
|
|---|---|
| Published in |
Frontiers in Pharmacology, November 2017
|
| DOI | 10.3389/fphar.2017.00823 |
| Pubmed ID | |
| Authors |
Chun Xie, Ying Li, Lan-Lan Li, Xing-Xing Fan, Yu-Wei Wang, Chun-Li Wei, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao |
| Abstract |
KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule inhibitor compound 0375-0604 targeting KRAS by using molecular docking based virtual screening approach. Compound 0375-0604 had a good binding affinity to KRAS in vitro and exhibited cytotoxicity in oncogenic KRAS expressing NSCLC cell lines. Further mechanism study showed that compound 0375-0604 can block the formation of the complex of guanosine triphosphate (GTP) and KRAS in vitro. In addition, compound 0375-0604 inhibited KRAS downstream signaling pathway RAF/MEK/ERK and RAF/PI3K/AKT. Finally, we also found that this compound can inhibit the cell growth through G2/M cell cycle arrest and induce apoptosis on the NSCLC cell lines harboring KRAS mutation. Therefore, compound 0375-0604 may be considered as a potential KRAS inhibitor for treatment of NSCLC carrying KRAS oncogene. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 23% |
| Researcher | 11 | 18% |
| Student > Bachelor | 6 | 10% |
| Student > Master | 5 | 8% |
| Professor | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 20 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 11 | 18% |
| Biochemistry, Genetics and Molecular Biology | 10 | 16% |
| Agricultural and Biological Sciences | 6 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Medicine and Dentistry | 3 | 5% |
| Other | 4 | 7% |
| Unknown | 22 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2019.
All research outputs
#7,030,043
of 23,007,887 outputs
Outputs from Frontiers in Pharmacology
#2,940
of 16,313 outputs
Outputs of similar age
#114,092
of 325,276 outputs
Outputs of similar age from Frontiers in Pharmacology
#45
of 261 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 16,313 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,276 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 261 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.